Zacks Investment Research on MSN

QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test

Last week, QuidelOrtho Corporation QDEL announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the ...
Nasdaq

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

Designed for symptomatic individuals within six days of symptom onset, the QuickVue COVID-19 test is cleared for use in individuals aged 14 or older when self-testing, and in those aged two and older ...